Rep. Gilbert Ray Cisneros, Jr. Buys Revvity Inc. (NYSE:RVTY) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Revvity Inc. (NYSE:RVTY). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $15,001 and $50,000 in Revvity stock on May 4th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.

Revvity Trading Down 2.7%

Shares of RVTY opened at $101.28 on Thursday. The company has a market capitalization of $11.30 billion, a P/E ratio of 48.46, a P/E/G ratio of 2.28 and a beta of 1.11. Revvity Inc. has a one year low of $81.22 and a one year high of $118.30. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 1.72. The stock has a 50-day moving average price of $94.40 and a 200 day moving average price of $97.72.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The firm had revenue of $711.12 million during the quarter, compared to the consensus estimate of $704.07 million. During the same quarter in the prior year, the business posted $1.01 earnings per share. Revvity’s revenue for the quarter was up 7.0% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. Sell-side analysts forecast that Revvity Inc. will post 5.25 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. Revvity’s dividend payout ratio is currently 13.40%.

Institutional Trading of Revvity

A number of institutional investors and hedge funds have recently made changes to their positions in RVTY. Ascentis Independent Advisors acquired a new stake in shares of Revvity during the 1st quarter worth approximately $29,000. CYBER HORNET ETFs LLC acquired a new stake in shares of Revvity during the 2nd quarter worth approximately $32,000. Cromwell Holdings LLC raised its position in shares of Revvity by 141.4% during the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after purchasing an additional 198 shares during the period. MUFG Securities EMEA plc acquired a new stake in shares of Revvity during the 2nd quarter worth approximately $34,000. Finally, SJS Investment Consulting Inc. grew its holdings in Revvity by 5,210.0% in the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after buying an additional 521 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on RVTY shares. Barclays upped their price objective on Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. TD Cowen upped their price objective on Revvity from $115.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. The Goldman Sachs Group cut their price objective on Revvity from $110.00 to $95.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 14th. JPMorgan Chase & Co. cut their price objective on Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Finally, Weiss Ratings cut Revvity from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 13th. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $107.73.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.